Antiparasitic, anti-inflammatory, and immunomodulatory effects of Portulaca oleracea against Cryptosporidium parvum in experimentally infected immunosuppressed mice

Bibliographic Information
Authors: Abo Elqasem A.A.; El-Menyawy H.M.; Ahmed Amer D.A.-F.; El-Wakil E.S.
Journal: Beni-Suef University Journal of Basic and Applied Sciences
Publisher: Springer Science and Business Media Deutschland GmbH
Publication Date: 24 June 2026
Volume / Issue: Volume 15 / Issue 1
Article No.: 67
ISSN: 23148535
DOI: 10.1186/s43088-026-00795-2
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Gold Open Access
Authors and Affiliations
Abo Elqasem A.A., Immunology, Zoology and Entomology Department, Faculty of Science, Al-Azhar University (Girl’s Branch), Cairo, Egypt; El-Menyawy H.M., Parasitology, Zoology and Entomology Department, Faculty of Science, Al-Azhar University (Girl’s Branch), Cairo, Egypt; Ahmed Amer D.A.-F., Department of Medical Parasitology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt; El-Wakil E.S., Department of Parasitology, Theodor Bilharz Research Institute, Kornaish El-Nile St., Giza, 12411, Egypt
Abstract
Background: Cryptosporidium infection poses a significant threat to immunocompromised hosts, and effective treatment options are limited. Portulaca oleracea, commonly known as Purslane, has been traditionally used in folk medicine for its potential therapeutic properties. This study investigated the anti-Cryptosporidium activities and anti-inflammatory properties of Portulaca in immunosuppressed mice. Methods: Forty female mice were rendered immunosuppressed by oral administration of dexamethasone for 14 consecutive days. Following immunosuppression, the animals were randomly divided into 5 groups (8 mice per group): Group 1 (Is) was immunosuppressed and non-infected. Group 2 (IsI): immunosuppressed infected with Cryptosporidium. Group 3 (IsN): immunosuppressed infected nitazoxanide-treated. Group 4 (IsP): immunosuppressed infected and treated with Portulaca methanolic extraction. Group 5 (IsNP): immunosuppressed infected and received a combination of the methanolic extract of Portulaca and nitazoxanide. Oocyst count, IFN-γ and IL-17 levels, and histological and immunohistochemical (tumor necrosis factor-α) examination of intestinal tissue were conducted. Results: Our results suggested that Portulaca extract significantly reduced Cryptosporidium infection in immunosuppressed mice, as evidenced by a 65% decrease in oocyst count. Moreover, treatment with Portulaca attenuated inflammation, as indicated by reduced cytokine levels: IFN-γ and IL-17 decreased to 94.8 ± 27.23 and 134.83 ± 29.4, respectively, in the IsP group compared with the IsI group (194.5 ± 37.73 and 353.23 ± 64.4). A significant reduction in IFN-γ and IL-17 was observed in the IsPN group, with levels of 47.77 ± 10.6 and 87.73 ± 39.16, respectively. Histological examination improved intestinal architecture, with reduced tissue damage and inflammatory cell infiltration. Additionally, quantitative immunohistochemical analysis revealed a marked decrease in tumor necrosis factor-α expression from 37.93% in the IsI group to 1.075% and 2.727% in IsP and IsNP groups, respectively. Conclusions: Portulaca oleracea demonstrated significant anti-Cryptosporidium activity through immunomodulatory effects, reflected by reduced IFN-γ and IL-17 levels, offering novel insights into its therapeutic potential as an immunomodulatory agent in cryptosporidiosis. Clinical trial number: Not applicable. © The Author(s) 2026.
Keywords
Cryptosporidium parvum; IFN-γ; IL-17; Immunosuppression; Oocyst; Portulaca oleracea
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
